Aptose Clarifies CEO Employment Terms and Compensation Obligations

The latest announcement is out from Aptose Biosciences ( (TSE:APS) ).

On March 12, 2026, Aptose Biosciences Inc. and its Chairman, President and Chief Executive Officer, Dr. William Rice, executed a First Amendment to his Second Amended and Restated Employment Agreement originally dated April 29, 2024. The amendment confirms that no deferred compensation plan was ever created, no deferred compensation was earned or is owed to Dr. Rice, and that he alone is responsible for any individual taxes, penalties and interest on all benefits paid or payable under his current and prior employment agreements, clarifying the company’s obligations and reducing potential liabilities related to his compensation arrangements.

The most recent analyst rating on (TSE:APS) stock is a Hold with a C$2.50 price target. To see the full list of analyst forecasts on Aptose Biosciences stock, see the TSE:APS Stock Forecast page.

Spark’s Take on APS Stock

According to Spark, TipRanks’ AI Analyst, APS is a Neutral.

The score is held back primarily by very weak financial performance (no revenue, ongoing cash burn, negative equity and rising debt). Positive corporate catalysts (promising trial results and a pending acquisition) provide meaningful offset, while technical indicators are mixed-to-weak and valuation metrics are not supportive due to negative earnings and no dividend.

To see Spark’s full report on APS stock, click here.

More about Aptose Biosciences

Aptose Biosciences Inc. is a biotechnology company focused on developing oncology therapeutics. The company’s leadership includes Chairman, President and Chief Executive Officer Dr. William Rice, whose employment arrangements are a key element of its executive governance and compensation structure.

YTD Price Performance: 5.19%

Average Trading Volume: 3,993

Technical Sentiment Signal: Sell

Current Market Cap: C$5.69M

See more insights into APS stock on TipRanks’ Stock Analysis page.